GlaxoSmithKline (NYSE:GSK) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of GlaxoSmithKline (NYSE:GSKGet Rating) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday.

Several other research firms also recently commented on GSK. Zacks Investment Research downgraded shares of GlaxoSmithKline from a buy rating to a hold rating and set a $46.00 target price on the stock. in a report on Tuesday, January 4th. Stifel Nicolaus started coverage on shares of GlaxoSmithKline in a report on Monday, February 28th. They issued a hold rating on the stock. DZ Bank downgraded shares of GlaxoSmithKline from a buy rating to a hold rating in a report on Friday, February 11th. JPMorgan Chase & Co. boosted their target price on shares of GlaxoSmithKline from GBX 1,740 ($21.74) to GBX 1,900 ($23.74) in a report on Thursday, April 28th. Finally, Barclays boosted their target price on shares of GlaxoSmithKline from GBX 1,775 ($22.17) to GBX 1,800 ($22.49) in a report on Friday, April 29th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of Hold and an average price target of $1,248.67.

Shares of NYSE GSK opened at $45.12 on Tuesday. The firm has a 50 day moving average of $43.68 and a 200 day moving average of $43.34. The company has a current ratio of 1.19, a quick ratio of 0.95 and a debt-to-equity ratio of 1.29. The firm has a market capitalization of $114.69 billion, a price-to-earnings ratio of 16.29, a price-to-earnings-growth ratio of 2.02 and a beta of 0.64. GlaxoSmithKline has a 12-month low of $37.43 and a 12-month high of $46.97.

GlaxoSmithKline (NYSE:GSKGet Rating) last issued its quarterly earnings results on Wednesday, February 9th. The pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.06. GlaxoSmithKline had a net margin of 14.03% and a return on equity of 28.13%. The business had revenue of $12.84 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Sell-side analysts predict that GlaxoSmithKline will post 3.17 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 7th. Shareholders of record on Friday, February 25th were given a dividend of $0.615 per share. The ex-dividend date was Thursday, February 24th. This represents a $2.46 annualized dividend and a yield of 5.45%. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.52. GlaxoSmithKline’s dividend payout ratio (DPR) is 85.92%.

A number of hedge funds have recently added to or reduced their stakes in GSK. Two Sigma Investments LP lifted its position in GlaxoSmithKline by 4,645.1% during the third quarter. Two Sigma Investments LP now owns 3,457,267 shares of the pharmaceutical company’s stock valued at $132,102,000 after purchasing an additional 3,384,408 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of GlaxoSmithKline by 5,412.8% in the third quarter. Two Sigma Advisers LP now owns 3,322,366 shares of the pharmaceutical company’s stock valued at $126,948,000 after acquiring an additional 3,262,100 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of GlaxoSmithKline by 107.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,726,412 shares of the pharmaceutical company’s stock valued at $142,386,000 after acquiring an additional 1,929,345 shares during the period. Acadian Asset Management LLC raised its stake in shares of GlaxoSmithKline by 481.3% in the fourth quarter. Acadian Asset Management LLC now owns 1,788,114 shares of the pharmaceutical company’s stock valued at $78,830,000 after acquiring an additional 1,480,492 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of GlaxoSmithKline by 39.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,796,835 shares of the pharmaceutical company’s stock valued at $211,540,000 after acquiring an additional 1,365,400 shares during the period. Institutional investors and hedge funds own 32.76% of the company’s stock.

GlaxoSmithKline Company Profile (Get Rating)

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Read More

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.